Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer

J. Sven D Mieog, Susan L. Troyan, Merlijn Hutteman, Kevin J. Donohoe, Joost R. Van Der Vorst, Alan Stockdale, Gerrit Jan Liefers, Hak Soo Choi, Summer Gibbs, Hein Putter, Sylvain Gioux, Peter J K Kuppen, Yoshitomo Ashitate, Clemens W G M Löwik, Vincent T H B M Smit, Rafiou Oketokoun, Long H. Ngo, Cornelis J H Van De Velde, John V. Frangioni, Alexander L. Vahrmeijer

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Background: Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer requires optimized imaging systems and lymphatic tracers. Materials and Methods: A small, portable version of the FLARE imaging system, termed Mini-FLARE, was developed for capturing color video and two semi-independent channels of NIR fluorescence (700 and 800 nm) in real time. Initial optimization of lymphatic tracer dose was performed using 35-kg Yorkshire pigs and a 6-patient pilot clinical trial. More refined optimization was performed in 24 consecutive breast cancer patients. All patients received the standard of care using 99mTechnetium-nanocolloid and patent blue. In addition, 1.6 ml of indocyanine green adsorbed to human serum albumin (ICG:HSA) was injected directly after patent blue at the same location. Patients were allocated to 1 of 8 escalating ICG:HSA concentration groups from 50 to 1000 μM. Results: The Mini-FLARE system was positioned easily in the operating room and could be used up to 13 in. from the patient. Mini-FLARE enabled visualization of lymphatic channels and SLNs in all patients. A total of 35 SLNs (mean = 1.45, range 1-3) were detected: 35 radioactive (100%), 30 blue (86%), and 35 NIR fluorescent (100%). Contrast agent quenching at the injection site and dilution within lymphatic channels were major contributors to signal strength of the SLN. Optimal injection dose of ICG:HSA ranged between 400 and 800 μM. No adverse reactions were observed. Conclusions: We describe the clinical translation of a new NIR fluorescence imaging system and define the optimal ICG:HSA dose range for SLN mapping in breast cancer.

Original languageEnglish (US)
Pages (from-to)2483-2491
Number of pages9
JournalAnnals of Surgical Oncology
Volume18
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Lymphatic System
Indocyanine Green
Breast Neoplasms
Serum Albumin
Injections
Optical Imaging
Operating Rooms
Standard of Care
Contrast Media
Sentinel Lymph Node
Swine
Color
Fluorescence
Clinical Trials

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Mieog, J. S. D., Troyan, S. L., Hutteman, M., Donohoe, K. J., Van Der Vorst, J. R., Stockdale, A., ... Vahrmeijer, A. L. (2011). Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Annals of Surgical Oncology, 18(9), 2483-2491. https://doi.org/10.1245/s10434-011-1566-x

Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. / Mieog, J. Sven D; Troyan, Susan L.; Hutteman, Merlijn; Donohoe, Kevin J.; Van Der Vorst, Joost R.; Stockdale, Alan; Liefers, Gerrit Jan; Choi, Hak Soo; Gibbs, Summer; Putter, Hein; Gioux, Sylvain; Kuppen, Peter J K; Ashitate, Yoshitomo; Löwik, Clemens W G M; Smit, Vincent T H B M; Oketokoun, Rafiou; Ngo, Long H.; Van De Velde, Cornelis J H; Frangioni, John V.; Vahrmeijer, Alexander L.

In: Annals of Surgical Oncology, Vol. 18, No. 9, 09.2011, p. 2483-2491.

Research output: Contribution to journalArticle

Mieog, JSD, Troyan, SL, Hutteman, M, Donohoe, KJ, Van Der Vorst, JR, Stockdale, A, Liefers, GJ, Choi, HS, Gibbs, S, Putter, H, Gioux, S, Kuppen, PJK, Ashitate, Y, Löwik, CWGM, Smit, VTHBM, Oketokoun, R, Ngo, LH, Van De Velde, CJH, Frangioni, JV & Vahrmeijer, AL 2011, 'Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer', Annals of Surgical Oncology, vol. 18, no. 9, pp. 2483-2491. https://doi.org/10.1245/s10434-011-1566-x
Mieog, J. Sven D ; Troyan, Susan L. ; Hutteman, Merlijn ; Donohoe, Kevin J. ; Van Der Vorst, Joost R. ; Stockdale, Alan ; Liefers, Gerrit Jan ; Choi, Hak Soo ; Gibbs, Summer ; Putter, Hein ; Gioux, Sylvain ; Kuppen, Peter J K ; Ashitate, Yoshitomo ; Löwik, Clemens W G M ; Smit, Vincent T H B M ; Oketokoun, Rafiou ; Ngo, Long H. ; Van De Velde, Cornelis J H ; Frangioni, John V. ; Vahrmeijer, Alexander L. / Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. In: Annals of Surgical Oncology. 2011 ; Vol. 18, No. 9. pp. 2483-2491.
@article{38c9dd000a79407786ed39ca48fbb06f,
title = "Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer",
abstract = "Background: Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer requires optimized imaging systems and lymphatic tracers. Materials and Methods: A small, portable version of the FLARE imaging system, termed Mini-FLARE, was developed for capturing color video and two semi-independent channels of NIR fluorescence (700 and 800 nm) in real time. Initial optimization of lymphatic tracer dose was performed using 35-kg Yorkshire pigs and a 6-patient pilot clinical trial. More refined optimization was performed in 24 consecutive breast cancer patients. All patients received the standard of care using 99mTechnetium-nanocolloid and patent blue. In addition, 1.6 ml of indocyanine green adsorbed to human serum albumin (ICG:HSA) was injected directly after patent blue at the same location. Patients were allocated to 1 of 8 escalating ICG:HSA concentration groups from 50 to 1000 μM. Results: The Mini-FLARE system was positioned easily in the operating room and could be used up to 13 in. from the patient. Mini-FLARE enabled visualization of lymphatic channels and SLNs in all patients. A total of 35 SLNs (mean = 1.45, range 1-3) were detected: 35 radioactive (100{\%}), 30 blue (86{\%}), and 35 NIR fluorescent (100{\%}). Contrast agent quenching at the injection site and dilution within lymphatic channels were major contributors to signal strength of the SLN. Optimal injection dose of ICG:HSA ranged between 400 and 800 μM. No adverse reactions were observed. Conclusions: We describe the clinical translation of a new NIR fluorescence imaging system and define the optimal ICG:HSA dose range for SLN mapping in breast cancer.",
author = "Mieog, {J. Sven D} and Troyan, {Susan L.} and Merlijn Hutteman and Donohoe, {Kevin J.} and {Van Der Vorst}, {Joost R.} and Alan Stockdale and Liefers, {Gerrit Jan} and Choi, {Hak Soo} and Summer Gibbs and Hein Putter and Sylvain Gioux and Kuppen, {Peter J K} and Yoshitomo Ashitate and L{\"o}wik, {Clemens W G M} and Smit, {Vincent T H B M} and Rafiou Oketokoun and Ngo, {Long H.} and {Van De Velde}, {Cornelis J H} and Frangioni, {John V.} and Vahrmeijer, {Alexander L.}",
year = "2011",
month = "9",
doi = "10.1245/s10434-011-1566-x",
language = "English (US)",
volume = "18",
pages = "2483--2491",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer

AU - Mieog, J. Sven D

AU - Troyan, Susan L.

AU - Hutteman, Merlijn

AU - Donohoe, Kevin J.

AU - Van Der Vorst, Joost R.

AU - Stockdale, Alan

AU - Liefers, Gerrit Jan

AU - Choi, Hak Soo

AU - Gibbs, Summer

AU - Putter, Hein

AU - Gioux, Sylvain

AU - Kuppen, Peter J K

AU - Ashitate, Yoshitomo

AU - Löwik, Clemens W G M

AU - Smit, Vincent T H B M

AU - Oketokoun, Rafiou

AU - Ngo, Long H.

AU - Van De Velde, Cornelis J H

AU - Frangioni, John V.

AU - Vahrmeijer, Alexander L.

PY - 2011/9

Y1 - 2011/9

N2 - Background: Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer requires optimized imaging systems and lymphatic tracers. Materials and Methods: A small, portable version of the FLARE imaging system, termed Mini-FLARE, was developed for capturing color video and two semi-independent channels of NIR fluorescence (700 and 800 nm) in real time. Initial optimization of lymphatic tracer dose was performed using 35-kg Yorkshire pigs and a 6-patient pilot clinical trial. More refined optimization was performed in 24 consecutive breast cancer patients. All patients received the standard of care using 99mTechnetium-nanocolloid and patent blue. In addition, 1.6 ml of indocyanine green adsorbed to human serum albumin (ICG:HSA) was injected directly after patent blue at the same location. Patients were allocated to 1 of 8 escalating ICG:HSA concentration groups from 50 to 1000 μM. Results: The Mini-FLARE system was positioned easily in the operating room and could be used up to 13 in. from the patient. Mini-FLARE enabled visualization of lymphatic channels and SLNs in all patients. A total of 35 SLNs (mean = 1.45, range 1-3) were detected: 35 radioactive (100%), 30 blue (86%), and 35 NIR fluorescent (100%). Contrast agent quenching at the injection site and dilution within lymphatic channels were major contributors to signal strength of the SLN. Optimal injection dose of ICG:HSA ranged between 400 and 800 μM. No adverse reactions were observed. Conclusions: We describe the clinical translation of a new NIR fluorescence imaging system and define the optimal ICG:HSA dose range for SLN mapping in breast cancer.

AB - Background: Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer requires optimized imaging systems and lymphatic tracers. Materials and Methods: A small, portable version of the FLARE imaging system, termed Mini-FLARE, was developed for capturing color video and two semi-independent channels of NIR fluorescence (700 and 800 nm) in real time. Initial optimization of lymphatic tracer dose was performed using 35-kg Yorkshire pigs and a 6-patient pilot clinical trial. More refined optimization was performed in 24 consecutive breast cancer patients. All patients received the standard of care using 99mTechnetium-nanocolloid and patent blue. In addition, 1.6 ml of indocyanine green adsorbed to human serum albumin (ICG:HSA) was injected directly after patent blue at the same location. Patients were allocated to 1 of 8 escalating ICG:HSA concentration groups from 50 to 1000 μM. Results: The Mini-FLARE system was positioned easily in the operating room and could be used up to 13 in. from the patient. Mini-FLARE enabled visualization of lymphatic channels and SLNs in all patients. A total of 35 SLNs (mean = 1.45, range 1-3) were detected: 35 radioactive (100%), 30 blue (86%), and 35 NIR fluorescent (100%). Contrast agent quenching at the injection site and dilution within lymphatic channels were major contributors to signal strength of the SLN. Optimal injection dose of ICG:HSA ranged between 400 and 800 μM. No adverse reactions were observed. Conclusions: We describe the clinical translation of a new NIR fluorescence imaging system and define the optimal ICG:HSA dose range for SLN mapping in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=80052722437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052722437&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-1566-x

DO - 10.1245/s10434-011-1566-x

M3 - Article

C2 - 21360250

AN - SCOPUS:80052722437

VL - 18

SP - 2483

EP - 2491

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 9

ER -